Executive Committee (as of April 2021)
The Executive Committee discusses important matters of management across Astellas. It is chaired by the Representative Director, President and CEO. Extended members include the officers responsible for research, development and pharmaceutical technology capabilities together with the officers responsible for each commercial region, and these members participate in any necessary discussions at the request of the chairman.
Standing Members
Representative Director,
President and Chief Executive Officer (CEO) |
Kenji Yasukawa, Ph.D. |
Representative Director,
Executive Vice President,
Chief Strategy Officer (CStO) and
Chief Financial Officer (CFO) |
Naoki Okamura |
Chief Administrative Officer (CAO) and
Chief Ethics & Compliance Officer (CECO) |
Fumiaki Sakurai |
| Chief Medical Officer (CMO) |
Bernhardt Zeiher, M.D. |
| Chief Commercial Officer (CCO) |
Yukio Matsui |
| Chief Scientific Officer (CScO) |
Yoshitsugu Shitaka, Ph.D. |
| Chief Business Officer (CBO) |
Percival Barretto-Ko |
| General Counsel (GC) |
Catherine Levitt |
Extended Members
| President, Drug Discovery Research |
Yoshitsugu Shitaka* |
| President, Pharmaceutical Technology |
Hideki Shima |
| President, Development |
Steven Benner |
| President, Established Markets Commercial |
Dirk Kosche |
| President, Greater China Commercial |
Hiroshi Hamaguchi |
| President, International Markets Commercial |
Claus Zieler |
| President, Japan Commercial |
Yasuhiro Tsutsui |
| President, US Commercial |
Mark Reisenauer |
*Yoshitsugu Shitaka, Chief Scientific Officer, concurrently holds the position of President, Drug Discovery Research.
Group Management Structure (As of April 1, 2021)
